CA2991907A1 - Proteins and immunizing compositions containing klebsiella proteins and methods of use - Google Patents

Proteins and immunizing compositions containing klebsiella proteins and methods of use Download PDF

Info

Publication number
CA2991907A1
CA2991907A1 CA2991907A CA2991907A CA2991907A1 CA 2991907 A1 CA2991907 A1 CA 2991907A1 CA 2991907 A CA2991907 A CA 2991907A CA 2991907 A CA2991907 A CA 2991907A CA 2991907 A1 CA2991907 A1 CA 2991907A1
Authority
CA
Canada
Prior art keywords
seq
protein
composition
proteins
klebsiella
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA2991907A
Other languages
English (en)
French (fr)
Inventor
Douglas T. Burkhardt
Daryll Emery
Darren Straub
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epitopix LLC
Original Assignee
Epitopix LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epitopix LLC filed Critical Epitopix LLC
Publication of CA2991907A1 publication Critical patent/CA2991907A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0266—Klebsiella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/116—Polyvalent bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/26—Klebsiella (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2991907A 2015-07-10 2016-07-08 Proteins and immunizing compositions containing klebsiella proteins and methods of use Pending CA2991907A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562190947P 2015-07-10 2015-07-10
US62/190,947 2015-07-10
PCT/US2016/041614 WO2017011340A2 (en) 2015-07-10 2016-07-08 Proteins and immunizing compositions containing klebsiella proteins and methods of use

Publications (1)

Publication Number Publication Date
CA2991907A1 true CA2991907A1 (en) 2017-01-19

Family

ID=56555778

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2991907A Pending CA2991907A1 (en) 2015-07-10 2016-07-08 Proteins and immunizing compositions containing klebsiella proteins and methods of use

Country Status (7)

Country Link
US (3) US11000582B2 (https=)
EP (1) EP3319628A2 (https=)
JP (2) JP7222711B2 (https=)
CN (1) CN107921114A (https=)
CA (1) CA2991907A1 (https=)
MX (1) MX2018000395A (https=)
WO (1) WO2017011340A2 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03006038A (es) * 2001-01-03 2005-02-14 Willmar Poultry Co Inc Composiciones inmunizantes y metodos de uso.
US11000582B2 (en) * 2015-07-10 2021-05-11 Epitopix, Llc Proteins and immunizing compositions containing klebsiella proteins and methods of use
US10166280B2 (en) 2016-06-08 2019-01-01 Epitopix, Llc Polypeptides and immunizing compositions containing Bacillus polypeptides and methods of use
ES2945137T3 (es) 2017-02-10 2023-06-28 Epitopix Llc Proteínas y composiciones inmunitarias que contienen proteínas de Pasteurella y métodos de uso
AU2020263592B2 (en) * 2019-04-26 2026-03-19 Cornell University Klebsiella vaccine and methods of use
CN111647057B (zh) * 2020-05-07 2022-09-13 西南医科大学附属中医医院 一种伤寒沙门菌疫苗重组蛋白及其编码基因和它们的应用
JP2024540240A (ja) * 2021-10-29 2024-10-31 ヴァクシノヴァ ユーエス， インコーポレイテッド 感染症を防止するための方法および組成物
CN115975890A (zh) * 2023-02-02 2023-04-18 深圳元健生命科技有限公司 一种产气克雷伯氏菌及其应用
CN115798574B (zh) * 2023-02-06 2023-06-02 中国医学科学院北京协和医院 一种预测克雷伯氏菌属对美罗培南敏感性的系统及方法
CN119679930B (zh) * 2025-02-24 2025-07-25 吉林大学第一医院 一种肺炎克雷伯菌表面膜蛋白的应用和疫苗
CN120330106B (zh) * 2025-06-05 2025-08-26 云南省农业科学院茶叶研究所 一种产酸克雷伯氏菌株及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2644346B1 (fr) * 1989-03-20 1994-05-13 Rhone Merieux Vaccins contre les bacteries septicemiques, preparations d'antigenes de bacteries septicemiques, nouvelles bacteries et vecteurs pour la preparation de ces antigenes ou vaccins
DK0749321T3 (da) 1994-02-09 2007-03-12 Epitopix Llc Aktiv immunisering under anvendelse af et sideroforreceptorprotein
US5538733A (en) 1994-07-07 1996-07-23 Willmar Poultry Company, Inc. Method of priming an immune response in a one-day old animal
US6610836B1 (en) 1999-01-29 2003-08-26 Genome Therapeutics Corporation Nucleic acid amino acid sequences relating to Klebsiella pneumoniae for diagnostics and therapeutics
US6682754B2 (en) 1999-11-24 2004-01-27 Willmar Poultry Company, Inc. Ovo delivery of an immunogen containing implant
MXPA03006038A (es) 2001-01-03 2005-02-14 Willmar Poultry Co Inc Composiciones inmunizantes y metodos de uso.
AU2004274977B2 (en) * 2003-09-19 2011-06-23 Epitopix, Llc Campylobacter polypeptides and methods of use
US8007811B2 (en) 2005-02-14 2011-08-30 Epitopix, Llc Polypeptides and immunizing compositions containing gram positive polypeptides and methods of use
CN102015754A (zh) 2007-05-02 2011-04-13 英特塞尔股份公司 克雷伯菌（Klebsiella）抗原
BRPI1011856A2 (pt) 2009-03-23 2020-11-03 Epitopix, Llc polipeptídeos e composições de imunização contendo polipeptídeos gram-positivos e métodos de uso
WO2011125015A2 (en) * 2010-04-05 2011-10-13 Bar-Ilan University Protease-activatable pore-forming polypeptides
US11000582B2 (en) * 2015-07-10 2021-05-11 Epitopix, Llc Proteins and immunizing compositions containing klebsiella proteins and methods of use

Also Published As

Publication number Publication date
US20190070281A1 (en) 2019-03-07
US20240216494A1 (en) 2024-07-04
JP2021063084A (ja) 2021-04-22
WO2017011340A3 (en) 2017-04-13
EP3319628A2 (en) 2018-05-16
JP2018527405A (ja) 2018-09-20
CN107921114A (zh) 2018-04-17
MX2018000395A (es) 2018-05-23
US11872273B2 (en) 2024-01-16
US11000582B2 (en) 2021-05-11
WO2017011340A2 (en) 2017-01-19
JP7222711B2 (ja) 2023-02-15
US20210330776A1 (en) 2021-10-28

Similar Documents

Publication Publication Date Title
US11872273B2 (en) Proteins and immunizing compositions containing Klebsiella proteins and methods of use
US10086059B2 (en) Campylobacter polypeptides and methods of use
US20250255950A1 (en) Proteins and immunizing compositions containing pasteurella proteins and methods of use
MX2007001886A (es) Polipeptidos de fusobacteria y metodos de uso.
US12178866B2 (en) Polypeptides of fusobacterium and methods of use
BR122025008885A2 (pt) Composições, usos das mesmas, e kits

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210609

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20240725

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241230

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250204

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250204

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250707

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250707

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20251219

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260127